Long-term therapy of coronary artery disease: a vascular biology perspective.
When evaluating a patient with known coronary artery disease or a patient with hypercholesterolemia without overt clinical symptoms of coronary artery disease or other vascular disease, it is helpful to understand the vascular biology behind primary and secondary prevention. This article reviews the progression of the atherosclerotic plaque, endothelial function, and the impact of current modes of therapy.
Mathé
A J
AJ
Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth/Texas College of Osteopathic Medicine, 3500 Camp Bowie Blvd, Fort Worth, TX 76107-2644, USA. ajmathe@hsc.unt.edu
Clearfield
M B
MB
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000188:drug therapy; D003327:Coronary Disease / Q000188:drug therapy*; D018450:Disease Progression; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors